THE DEAL, AT A GLANCE
From the announcementSoley
01What it doesSoley is a asset into the clinic.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by the strong investor support from life sciences, expand our platform, life sciencesFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedSoley raised $200M Series C, announced 2026-01-07From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersSoley's Series C thesis is that $200M of new capital can move its AML cell stress drug and lead programs into the clinic while expanding its platform.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Soley · Financing Record
Explore source-linked visual explanations for Soley. Unsupported claims are withheld while source review continues.
Record 3444 · Recorded date: 2026-01-07
Explore company records →